Binge-Eating Disorder
Conditions
Keywords
Binge-Eating Disorder, Impulsivity, Obesity, Attention, Emotional regulation
Brief summary
* Binge Eating Disorder (BED) has been fairly recently introduced into the Diagnostic and Statistical Manual 5 psychiatric classification and its severity criteria are still not well established. * Moreover, it remains unclear whether BED is associated with greater metabolic severity or more somatic comorbidities, especially in obesity. * Improved BED severity staging could lead to a better definition of management strategies and , therefore, facilitate screening and care. The investigators' hypothesis is that an improved assessment of the impulsivity-compulsivity spectrum, emotional regulation, attentional impairment and somatic or psychiatric comorbidities will result in a better distinction between the severe form of BED (e.g., highly impulsive and somatically complicated) from milder form (e.g., more compulsive and less somatically complicated).
Interventions
OTHERObservational
(no intervention)
Sponsors
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Centre d'expertise Poids, Image et Alimentation (CEPIA)
Laval University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* men or women aged 1 * participants eligible for bariatric surgery (BMI\>40, or BMI\>35 with severe comorbidities) * participants scheduled for medical evaluation and treatment of obesity at the IUCPQ Obesity Clinic (BMI≥30) * participants scheduled for evaluation and treatment of BED at the CEPIA with obesity (BMI≥30) * for the group with BED: positive BEDS-7 screen and Binge Eating Scale score \>16; * for the control group: have a negative BEDS-7 screen and Binge Eating Scale score\<12 * be fluent in French and able to consent.
Exclusion criteria
: * participants with severe neurological disorder and/or major neurocognitive deficits; * participants with previous bariatric surgery or with introduction or change of anti-obesity medication (liraglutide or naltrexone/bupropion) in the previous 3 months; * participants who cannot read and/or understand French; * participants under guardianship or curatorship; * participants already included in a study with a conflict of interest with this study; * inability to use a computer or iPad; * inability to access an Internet connection or to visit one of the inclusion sites. Secondary
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Physical and psychological comorbidities | Inclusion | Number of current associated comorbidities to patient with and without BED |
| Binge Eating Scale score | Inclusion | To assess binge eating severity based on the 16-item scale developed by Gormally et al in 1982 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting blood glucose in mmol/L | Inclusion | Routine clinical biological markers, when available. |
| Glycated hemoglobin (HbA1C) in % | Inclusion | Routine clinical biological markers, when available. |
| Insulin in pmol/L | Inclusion | Routine clinical biological markers, when available. |
| Body Mass Index in kg.m-2 | Inclusion | \[Anthropometric markers\] weight and height will be combined to report BMI in kg/m\^2 |
| Percentage of fat mass in % | Inclusion | \[Anthropometric markers\] Based on impedance data, percentage fat mass will be reported when available |
| Waist and hip circumferences in cm | Inclusion | \[Anthropometric markers\] Waist, hip circumference and Waist-hip ratio will be reported in cm when available |
| Visceral Adiposity Index | Inclusion | The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity. |
| UPPS-P Impulsive Behavior Scale short version, S-UPPS-P | Inclusion | To assess the Impulsivity-compulsivity spectrum |
| Triglycerides in mmol/L | Inclusion | Routine clinical biological markers; part of lipidic profile (when available) |
| Stop Signal Task | Inclusion | To assess the Impulsivity-compulsivity spectrum |
| Difficulties in emotion regulation scale short form, DERS | Inclusion | To assess the emotion regulation spectrum |
| Emotional Go / No-Go Task | Inclusion | To assess the emotion regulation spectrum |
| Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, ASRS | Inclusion | To assess attentional functions |
| Integrated Visual and Auditory Continuous Performance Test, IVA-CPT | Inclusion | To assess attentional functions |
| General Anxiety Disorder (GAD)-7 | Inclusion | To assess anxiety disorders risk |
| Patient Health Questionnaire (PHQ)-9 | Inclusion | To assess depression disorder risk |
| Obsessive-Compulsive Inventory-Revised, OCI-R | Inclusion | To assess the Impulsivity-compulsivity spectrum |
| Cholesterol HDL and LDL in mmol/L | Inclusion | Routine clinical biological markers; part of lipidic profile (when available) |
Countries
Canada
Contacts
Primary ContactSylvain Iceta, MD, PhD
Backup ContactPelletier Melissa
Outcome results
None listed